Darío Rubio-Rodríguez

555 total citations
63 papers, 377 citations indexed

About

Darío Rubio-Rodríguez is a scholar working on Cardiology and Cardiovascular Medicine, Infectious Diseases and Epidemiology. According to data from OpenAlex, Darío Rubio-Rodríguez has authored 63 papers receiving a total of 377 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cardiology and Cardiovascular Medicine, 15 papers in Infectious Diseases and 14 papers in Epidemiology. Recurrent topics in Darío Rubio-Rodríguez's work include Health Systems, Economic Evaluations, Quality of Life (13 papers), Atrial Fibrillation Management and Outcomes (8 papers) and Antifungal resistance and susceptibility (5 papers). Darío Rubio-Rodríguez is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (13 papers), Atrial Fibrillation Management and Outcomes (8 papers) and Antifungal resistance and susceptibility (5 papers). Darío Rubio-Rodríguez collaborates with scholars based in Spain, Switzerland and Germany. Darío Rubio-Rodríguez's co-authors include Carlos Rubio-Terrés, Santiago Grau, Ginés Escolar, José Luis Zamorano, Emilio Bouza, Miguel Salavert, Josep Comín‐Colet, Ángel Asensio, Gonzalo Barón‐Esquivias and Piotr Ponikowski and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Frontiers in Pharmacology.

In The Last Decade

Darío Rubio-Rodríguez

54 papers receiving 374 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Darío Rubio-Rodríguez Spain 12 116 115 103 55 50 63 377
Harshad Amin United States 13 203 1.8× 84 0.7× 97 0.9× 42 0.8× 25 0.5× 27 477
Francesco Del Sole Italy 9 182 1.6× 65 0.6× 92 0.9× 16 0.3× 31 0.6× 13 446
André Gaasbeek Netherlands 10 131 1.1× 152 1.3× 111 1.1× 10 0.2× 15 0.3× 16 588
Charbel F Matar Lebanon 11 186 1.6× 40 0.3× 36 0.3× 14 0.3× 66 1.3× 21 457
A Barbari Lebanon 12 50 0.4× 60 0.5× 62 0.6× 14 0.3× 44 0.9× 60 526
Lisa Bernard United States 13 35 0.3× 63 0.5× 25 0.2× 38 0.7× 32 0.6× 27 458
Marko Kavčič Slovenia 13 54 0.5× 85 0.7× 41 0.4× 11 0.2× 89 1.8× 34 439
José Pardos‐Gea Spain 12 41 0.4× 57 0.5× 138 1.3× 5 0.1× 111 2.2× 23 470
Rajesh Rajan Kuwait 9 112 1.0× 41 0.4× 71 0.7× 4 0.1× 27 0.5× 57 250
Elmukhtar Habas Qatar 10 29 0.3× 56 0.5× 44 0.4× 6 0.1× 29 0.6× 49 302

Countries citing papers authored by Darío Rubio-Rodríguez

Since Specialization
Citations

This map shows the geographic impact of Darío Rubio-Rodríguez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darío Rubio-Rodríguez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darío Rubio-Rodríguez more than expected).

Fields of papers citing papers by Darío Rubio-Rodríguez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darío Rubio-Rodríguez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darío Rubio-Rodríguez. The network helps show where Darío Rubio-Rodríguez may publish in the future.

Co-authorship network of co-authors of Darío Rubio-Rodríguez

This figure shows the co-authorship network connecting the top 25 collaborators of Darío Rubio-Rodríguez. A scholar is included among the top collaborators of Darío Rubio-Rodríguez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darío Rubio-Rodríguez. Darío Rubio-Rodríguez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cacicedo, Jon, et al.. (2025). Cost–effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain. Journal of Comparative Effectiveness Research. 14(2). e240116–e240116.
2.
Castro, Antonio Arjona, Carlos Rubio-Terrés, Darío Rubio-Rodríguez, et al.. (2024). HIV-1 resistance and virological failure to treatment with the integrase inhibitors bictegravir, cabotegravir, and dolutegravir: a systematic literature review. PubMed. 26(2). 67–79. 2 indexed citations
3.
4.
Formiga, Françesc, Pablo García‐Pavía, Francisco Javier Martín‐Sánchez, et al.. (2021). Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain. Expert Review of Pharmacoeconomics & Outcomes Research. 21(5). 1127–1133. 8 indexed citations
5.
Rubio-Terrés, Carlos, et al.. (2020). <p>Analysis of the Health and Budgetary Impact of Chondroitin Sulfate Prescription in the Treatment of Knee Osteoarthritis Compared to NSAIDs and COXIBs</p>. ClinicoEconomics and Outcomes Research. Volume 12. 505–514. 3 indexed citations
6.
7.
Sánchez-Cenizo, Laura, et al.. (2019). <p>Burden of diabetes mellitus in patients with acromegaly treated with second-line pharmacotherapy in Spain</p>. ClinicoEconomics and Outcomes Research. Volume 11. 465–475.
8.
Rubio-Terrés, Carlos, José María Aguado, Benito Almirante, et al.. (2019). Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain. European Journal of Clinical Microbiology & Infectious Diseases. 38(6). 1105–1111. 14 indexed citations
9.
Carvalho, S.M.P., et al.. (2016). Cost-effectiveness Analysis of Rituximab Maintenance Treatment in Patients With Follicular Lymphoma who Respond to First Line Induction Therapy in Portugal. SHILAP Revista de lepidopterología. 1 indexed citations
10.
Rubio-Terrés, Carlos, et al.. (2016). Cost analysis of the adverse reactions of bipolar disorder treatment with aripiprazole and olanzapine in Spain.. PubMed. 42(5). 242–9. 1 indexed citations
11.
12.
13.
Rubio-Terrés, Carlos & Darío Rubio-Rodríguez. (2015). Economic Evaluation of Chondroitin Sulfate and Non-Steroidal Antiinflammatory Drugs for The Treatment of Osteoarthritis. Value in Health. 18(7). A640–A640.
14.
Isla, Dolores, Javier de Castro, Óscar Juan, et al.. (2015). Adverse Events Costs Associated With Erlotinib Or Afatinib In Non-Small Cell Lung Cancer (Nsclc) Patients With Egfr Mutation-Positive Tumours. Value in Health. 18(7). A429–A429. 1 indexed citations
15.
Rubio-Terrés, Carlos, José Manuel Soria, Pierre‐Emmanuel Morange, et al.. (2015). Economic Analysis of Thrombo inCode, a Clinical–Genetic Function for Assessing the Risk of Venous Thromboembolism. Applied Health Economics and Health Policy. 13(2). 233–242. 11 indexed citations
16.
Comín‐Colet, Josep, Darío Rubio-Rodríguez, Carlos Rubio-Terrés, et al.. (2015). A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain. Revista Española de Cardiología (English Edition). 68(10). 846–851. 19 indexed citations
17.
Arrieta, Francisco, Carlos Rubio-Terrés, Darío Rubio-Rodríguez, et al.. (2014). Estimación del impacto económico y sanitario de las complicaciones de la diabetes mellitus tipo 2 en la Comunidad de Madrid. Endocrinología y Nutrición. 61(4). 193–201. 16 indexed citations
18.
Rubio-Rodríguez, Darío, et al.. (2013). Cost-Effectiveness Analysis of Apixaban Versus Dabigatran for Prevention of Stroke in Patients with Non-Valvular Atrial Fibrillation in Spain. Value in Health. 16(7). A523–A523. 6 indexed citations
19.
Ruíz, Pablo, et al.. (2013). Cost-Utility of Rheumatoid Arthritis Monotherapy with Tocilizumab in Spain. Value in Health. 16(7). A565–A565.
20.
Rubio-Rodríguez, Darío. (2012). Análisis económico de la promoción intensiva y especializada de la lactancia materna en las unidades neonatales en España. Anales de Pediatría. 77(5). 297–308. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Harshad Amin Breakdown of academic impact, for papers by Francesco Del Sole Breakdown of academic impact, for papers by André Gaasbeek Breakdown of academic impact, for papers by Charbel F Matar Breakdown of academic impact, for papers by A Barbari Breakdown of academic impact, for papers by Lisa Bernard Breakdown of academic impact, for papers by Marko Kavčič Breakdown of academic impact, for papers by José Pardos‐Gea Breakdown of academic impact, for papers by Rajesh Rajan Breakdown of academic impact, for papers by Elmukhtar Habas
Rankless by CCL
2026